Press release
Hodgkin's Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others
Hodgkin's Lymphoma Pipeline
DelveInsight's, "Hodgkin's Lymphoma Pipeline Insight, 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hodgkin's Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hodgkin's Lymphoma Key Players
• Affimed Therapeutics
• ACD Therapeutics
• Cstone Pharmaceuticals
• 4SC
• TG Therapeutics
• And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Hodgkin's Lymphoma report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Some of Hodgkin's Lymphoma Therapies are:
• AFM 13
• Camidanlumab tesirine
• Sugemalimab
• Resminostat
• TGR-1202
• And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Current Hodgkin's Lymphoma Treatment Scenario and Hodgkin's Lymphoma Emerging Therapies:
• How many companies are developing Hodgkin's Lymphoma drugs?
• How many Hodgkin's Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin's Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin's Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hodgkin's Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents:
Introduction
Executive Summary
Hodgkin's Lymphoma: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Hodgkin's Lymphoma - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Hodgkin's Lymphoma companies' collaborations, Licensing, Acquisition -Deal Value Trends
Hodgkin's Lymphoma Collaboration Deals
Mid Stage Products (Phase II)
• Comparative Analysis
AFM 13:Affimed Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Camidanlumab tesirine: ACD Therapeutics
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Hodgkin's Lymphoma Key Companies
Hodgkin's Lymphoma Key Products
Hodgkin's Lymphoma- Unmet Needs
Hodgkin's Lymphoma- Market Drivers and Barriers
Hodgkin's Lymphoma- Future Perspectives and Conclusion
Hodgkin's Lymphoma Analyst Views
Hodgkin's Lymphoma Key Companies
Appendix
Request for Detailed TOC: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/hodgkins-lymphoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hodgkin's Lymphoma Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Affimed Therapeutics, ACD Therapeutics, Cstone Pharmaceuticals and Many Others here
News-ID: 2940300 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Hodgkin
Hodgkin Lymphoma Treatment Market Poised to Reach USD 15.70 Bn by 2030 at 8.3% C …
Opening Paragraph
According to a new report by Maximize Market Research, the global Hodgkin Lymphoma Treatment Market was valued at USD 8.98 billion in 2023 and is projected to reach nearly USD 15.70 billion by 2030, growing at a CAGR of 8.3%.
Curious to peek inside? Grab your sample copy of this report now:https://www.maximizemarketresearch.com/request-sample/124690/
Key Highlights
Market Size & CAGR: Valued at USD 8.98 Bn in 2023, forecast to grow to USD 15.70…
High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth: The Driving Engine …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non Hodgkin Lymphoma (NHL) Market Size Growth Forecast: What to Expect by 2025?
The market size for non hodgkin lymphoma (NHL) has consistently seen robust growth in recent times. It is anticipated to expand from $10.11 billion in 2024 to $11.01 billion in 2025, with a compound annual growth…
Breakthrough Treatments for Non-Hodgkin Lymphoma
The Business Research Company recently released a comprehensive report on the Global Non Hodgkin Lymphoma (NHL) Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The non hodgkin…
Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017 | Market R …
Market Research Hub (MRH) has recently published a latest market study to its online portal, which is titled as “Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H1 2017” This study offers professional analysis of the current state of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market.
Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1049067
Market Research HUB’s latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides…
Non-Hodgkin Lymphoma - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Non-Hodgkin Lymphoma - Heat Map and Analysis to its growing collection of premium market research reports.
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing)…
